ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,307.01
-0.27%
Dow Jones
39,671.04
-0.51%
US Dollar vs MXN
16.6546
-0.06%
Brent Oil
81.395
-0.17%
Bitcoin
69,279.34
0.26%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Milestone Pharmaceuticals Inc (MIST)

  7. Milestone Pharmaceuticals Inc (MIST) Noticias

MIST

Milestone Pharmaceuticals (MIST)

Milestone Pharmaceuticals Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:MIST
FechaHoraFuenteTítuloSímboloCompañía
22/05/202407:00GlobeNewswire Inc.Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT AwarenessNASDAQ:MISTMilestone Pharmaceuticals Inc
13/05/202406:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MISTMilestone Pharmaceuticals Inc
13/05/202405:59Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MISTMilestone Pharmaceuticals Inc
01/03/202415:52Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MISTMilestone Pharmaceuticals Inc
29/02/202406:00GlobeNewswire Inc.Milestone Pharmaceuticals Announces Pricing of $30.0 Million Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
28/02/202415:37GlobeNewswire Inc.Milestone Pharmaceuticals Announces Proposed Public Offering of Common Shares and Pre-Funded WarrantsNASDAQ:MISTMilestone Pharmaceuticals Inc
14/02/202419:56Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202307:54Dow Jones NewsMilestone Pharmaceuticals Shares Sink 24% After Receiving Rejection from FDANASDAQ:MISTMilestone Pharmaceuticals Inc
26/12/202306:57Dow Jones NewsMilestone Pharmaceuticals' Etripamil Nasal Spray Application Gets FDA's Refusal to File LetterNASDAQ:MISTMilestone Pharmaceuticals Inc
21/11/202306:00PR Newswire (Canada)Milestone Pharmaceuticals to Present at the Piper Sandler 35th Annual Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
13/11/202305:57PR Newswire (Canada)Milestone Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Clinical and Corporate UpdatesNASDAQ:MISTMilestone Pharmaceuticals Inc
11/11/202309:00PR Newswire (US)Milestone Pharmaceuticals Presents Positive Results from ReVeRA Phase 2 Study of Etripamil in AFib-RVR at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
09/11/202315:43Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:MISTMilestone Pharmaceuticals Inc
07/11/202306:00PR Newswire (US)Milestone Pharmaceuticals to Host Investor and Analyst Webcast to Review Data from ReVeRA Phase 2 Study of Etripamil in AFib-RVRNASDAQ:MISTMilestone Pharmaceuticals Inc
24/10/202306:00PR Newswire (US)Milestone Pharmaceuticals Announces Submission of New Drug Application to the U.S. FDA for EtripamilNASDAQ:MISTMilestone Pharmaceuticals Inc
06/10/202306:00PR Newswire (US)Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:MISTMilestone Pharmaceuticals Inc
27/09/202306:00PR Newswire (US)Milestone Pharmaceuticals Announces Etripamil AFib-RVR Study is Selected for Featured Science Presentation at the American Heart Association Scientific Sessions 2023NASDAQ:MISTMilestone Pharmaceuticals Inc
05/09/202306:00PR Newswire (US)Milestone Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
10/08/202306:35PR Newswire (Canada)Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate UpdateNASDAQ:MISTMilestone Pharmaceuticals Inc
20/06/202306:00PR Newswire (US)Milestone Pharmaceuticals Announces Publication of Results from Phase 3 RAPID Clinical Trial of Etripamil Nasal Spray in Patients with PSVT in The LancetNASDAQ:MISTMilestone Pharmaceuticals Inc
09/06/202315:23Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:MISTMilestone Pharmaceuticals Inc
01/06/202306:00PR Newswire (Canada)Milestone Pharmaceuticals to Present at the Jefferies Healthcare ConferenceNASDAQ:MISTMilestone Pharmaceuticals Inc
31/05/202305:02Edgar (US Regulatory)Amended Annual Report (10-k/a)NASDAQ:MISTMilestone Pharmaceuticals Inc
30/05/202305:07Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MISTMilestone Pharmaceuticals Inc
22/05/202306:00PR Newswire (Canada)Milestone Pharmaceuticals Announces Presentation of Data from Analysis of Etripamil Nasal Spray in Patients Experiencing Atrial Fibrillation with Rapid Ventricular RateNASDAQ:MISTMilestone Pharmaceuticals Inc
15/05/202316:22Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:MISTMilestone Pharmaceuticals Inc
11/05/202306:25Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:MISTMilestone Pharmaceuticals Inc
11/05/202306:16PR Newswire (US)Milestone Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Clinical and Corporate UpdateNASDAQ:MISTMilestone Pharmaceuticals Inc
08/05/202306:00PR Newswire (Canada)Milestone Pharmaceuticals to Host Virtual Key Opinion Leader Event on Etripamil for the Treatment of Atrial Fibrillation with Rapid Ventricular RateNASDAQ:MISTMilestone Pharmaceuticals Inc
28/04/202316:22Edgar (US Regulatory)Securities Registration: Employee Benefit Plan (s-8)NASDAQ:MISTMilestone Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIST

Su Consulta Reciente

NASDAQ
AMIC
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados